logo-loader
viewPropanc Biopharma, Inc.

Propanc at final stages of completing manufacturing steps to file first clinical trial application

Propanc Biopharma, Inc. (OTCQB: PPCB) CEO James Nathanielsz sat down with Proactive Investors at the BIO CEO and Investor Conference in New York.

The biopharmaceutical company is developing new cancer treatments initially for patients suffering from pancreatic, ovarian and colorectal cancers.

Quick facts: Propanc Biopharma, Inc.

Price: 0.2517 USD

OTCQB:PPCB
Market: OTCQB
Market Cap: $330.11 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Minera Alamos announces 14-million-dollar deal with Osisko Gold Royalties to...

Minera Alamos (CVE: MAI) President Doug Ramshaw joined Steve Darling from Proactive Vancouver on Skype with details about a deal they have signed with Osisko Gold Royalties to help fund construction on their Santana project in Mexico. Ramshaw telling Proactive how the deal will work and the...

1 day, 12 hours ago

2 min read